Squarepoint
CADL icon

Squarepoint’s Candel Therapeutics CADL Stock Holding History

Squarepoint’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,737
Closed -$112K – 4315
2025
Q4 		$112K Sell
19,737
-11,225
-36% -$60.4K ﹤0.01% 4020
2025
Q3 		$158K Sell
30,962
-5,989
-16% -$34.6K ﹤0.01% 4012
2025
Q2 		$187K Sell
36,951
-38,127
-51% -$196K ﹤0.01% 3998
2025
Q1 		$424K Buy
75,078
+55,767
+289% +$456K ﹤0.01% 3459
2024
Q4 		$168K Buy
19,311
+8,962
+87% +$53K ﹤0.01% 4539
2024
Q3 		$71.7K Sell
10,349
-1,889
-15% -$11.7K ﹤0.01% 3939
2024
Q2 		$75.9K Buy
+12,238
New +$91.8K ﹤0.01% 3850

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's CADL Position: Q1 2026 in Review

Squarepoint sold out of Candel Therapeutics (CADL) in Q1 2026, closing a stake of 19,737 shares — an estimated $112K sold.

Squarepoint first reported a position in CADL in Q2 2024 and held it in 7 quarters. The position peaked at $424K in Q1 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Squarepoint reported no remaining Candel Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 19,737 Candel Therapeutics shares in Q1 2026, an estimated $112K.
  • Squarepoint first reported a position in Candel Therapeutics in Q2 2024 and held it in 7 quarters.
  • Squarepoint's Candel Therapeutics position peaked at $424K in Q1 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.